TCGA-B6-A0RT-01A-21R-A084-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 91
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.660
- INTERFERON_GAMMA_RESPONSE+0.640
- ALLOGRAFT_REJECTION+0.620
- IL6_JAK_STAT3_SIGNALING+0.470
- E2F_TARGETS+0.440
- G2M_CHECKPOINT+0.420
- INFLAMMATORY_RESPONSE+0.380
- COMPLEMENT+0.350
- WNT_BETA_CATENIN_SIGNALING+0.280
- IL2_STAT5_SIGNALING+0.180
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.500
- ESTROGEN_RESPONSE_LATE-0.430
- OXIDATIVE_PHOSPHORYLATION-0.420
- GLYCOLYSIS-0.370
- FATTY_ACID_METABOLISM-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- ANDROGEN_RESPONSE-0.330
- CHOLESTEROL_HOMEOSTASIS-0.300
- ADIPOGENESIS-0.290
- ANGIOGENESIS-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613734 | — | D | 0.917 |
| 2 | C3N-02922 | — | cohortMD2 | 0.891 |
| 3 | SRR8942983 | — | — | 0.880 |
| 4 | SRR29022833 | — | D | 0.878 |
| 5 | TCGA-C8-A12V-01A-11R-A115-07 | — | D | 0.878 |
| 6 | TCGA-A2-A0ST-01A-12R-A084-07 | — | D | 0.877 |
| 7 | TCGA-EW-A1OV-01A-11R-A144-07 | — | D | 0.874 |
| 8 | AUR-AF95-TTP1-A-1-0-R-A741-41 | — | D | 0.873 |
| 9 | SRR35579798 | — | D | 0.869 |
| 10 | TCGA-BH-A18V-06A-11R-A213-07 | — | D | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.660 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.640 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.620 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| APOPTOSIS | 0.030 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |